Nancy Moyer, MD
Internal Medicine · Hibbing, MNNPI 1508824889
Payments from drug & device makers
Across 21 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$59
- Otsuka America Pharmaceutical, Inc.$58
- AbbVie$57
- Alkermes, Inc.$42
- Teva Pharmaceuticals USA, Inc.$28
- Vanda Pharmaceuticals Inc.$27
- plus $51 from 4 others
What the payments were for
- Food & beverage$323100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 4 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| AbbVie(2 entities) | 3 | $57 |
| Alkermes, Inc. | 3 | $42 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 2 | $27 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Axsome Therapeutics, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$323 in reported general payments places this provider in the 90th percentile of 1,924 internal medicine providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $2,837 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 51 | $1,285 |
| Aripiprazole | 37 | $1,160 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $749 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 14 | $413 |
| Duloxetine Hcl | 18 | $341 |
| Clonazepam | 47 | $289 |
| Omeprazole | 23 | $181 |
| Oxycodone Hcl | 15 | $180 |
| Bupropion XlBupropion Hcl | 13 | $174 |
| Diazepam | 26 | $134 |
| Cyclobenzaprine Hcl | 14 | $122 |
| Dicyclomine Hcl | 11 | $121 |
| Alprazolam | 12 | $118 |
| Atorvastatin Calcium | 13 | $117 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Hibbing
- Eusebio Emmanuel FerrerApple Valley$10.7M
- Dylan ZyllaSaint Louis Park$4M
- Shannon DoyleMaplewood$3.2M
- Robert PignoloRochester$2M
- Thomas MartensBrooklyn Center$1.3M
- Gregory PolandRochester$494K
- Patricia WalkerSaint Paul$356K
- Beth ThielenMinneapolis$343K
- Bruce JohnsonSt. Paul$284K
- James JohnsonMinneapolis$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.